Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

BioAtla, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SAN DIEGO, AUG. 04, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT IT PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 7, 2025 AT 4:30 P.M. ET TO DISCUSS ITS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND PROVIDE BUSINESS HIGHLIGHTS.

BIOATLA TO ANNOUNCE SECOND QUARTER 2025 FINANCIAL RESULTSAND PROVIDE BUSINESS HIGHLIGHTS ON AUGUST 7, 2025

SAN DIEGO, JULY 17, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB) (THE COMPANY OR BIOATLA), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED AN ORAL PRESENTATION AT THE UPCOMING 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) TAT ASIA MEETING TO BE HELD IN HONG KONG SAR, CHINA FROM JULY 1820, 2025. ORAL PRESENTATION DETAILS:    TITLE:  FIRST-IN-HUMAN PHASE I STUDY OF A DUAL-CONDITIONALLY ACTIVE BIOLOGIC (CAB) EPCAM X CD3 BISPECIFIC T-CELL ENGAGER (TCE), BA3182, IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AUTHORS:  JENNIFER B.

BIOATLA ANNOUNCES UPCOMING ORAL PRESENTATION AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) TAT ASIA MEETING

ADVERSE EVENTS WERE GENERALLY LOW-GRADE, TRANSIENT, AND READILY MANAGEABLE ACHIEVED PRELIMINARY EVIDENCE OF PROLONGED TUMOR CONTROL AND TUMOR REDUCTIONS IN HEAVILY PRETREATED ADENOCARCINOMA PATIENTS DOSE ESCALATION NOW CONTINUING AT 1.2 MG WEEKLY BY SUBCUTANEOUS FLAT DOSING SAN DIEGO, JULY 03, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB) (THE COMPANY OR BIOATLA), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY PRESENTED FIRST-IN-HUMAN DATA IN A POSTER TITLED PRELIMINARY RESULTS FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF A DUAL-CONDITIONALLY BINDING CAB-EPCAM X CAB-CD3 BISPECIFIC T-CELL ENGAGER, BA3182, IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT THE EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) GASTROINTESTINAL CANCERS CONGRESS BEING HELD IN BARCELONA, SPAIN FROM JULY 25, 2025. IN THE ONGOING PHASE 1 DOSE-ESCALATION CLINICAL TRIAL, AS OF JUNE 20, 2025, 39 PATIENTS WITH HEAVILY PRETREATED METASTATIC ADENOCARCINOMA WERE DOSED IN COHORTS RANGING FROM 0.0026 MG TO 0.6 MG BA3182 QW, WITH EITHER 0, 1, OR 2 PRIMING DOSE(S) DELIVERED FOUR TO SEVEN DAYS PRIOR TO TREATMENT DOSING.

BIOATLA PRESENTS DATA FROM ONGOING DOSE ESCALATION OF BA3182, DUAL-CONDITIONALLY BINDING EPCAM X CD3 BISPECIFIC T-CELL ENGAGER, IN PATIENTS WITH TREATMENT REFRACTORY METASTATIC ADENOCARCINOMA AT THE 2025 EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY (ESMO) GASTROINTESTINAL CANCERS CONGRESS

45% OVERALL RESPONSE RATE (ORR) AND A 100% DISEASE CONTROL RATE (DCR) IN HPV+ OPSCC PATIENTS TREATED WITH A MEDIAN OF 3 PRIOR LINES OF THERAPY MARKED UNMET NEED EXISTS IN 2L+ HPV+ OPSCC PATIENTS; STANDARD OF CARE AGENTS (METHOTREXATE, DOCETAXEL, OR CETUXIMAB) REPORT AN ORR OF 3.4% PLAN TO FINALIZE PHASE 3 TRIAL DESIGN IN 2L+ HPV+ OPSCC WITH THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) SAN DIEGO, JUNE 02, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB) (THE COMPANY), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED DATA IN A POSTER TITLED, PHASE 2 TRIAL OF OZURIFTAMAB VEDOTIN (OZ-V), A CONDITIONALLY BINDING CAB-ROR2-ADC, IN PATIENTS WITH HEAVILY PRETREATED SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK. THE POSTER WILL BE PRESENTED TODAY AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING AT THE MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS.

BIOATLA PRESENTS PHASE 2 OZURIFTAMAB VEDOTIN (OZ-V) CLINICAL TRIAL DATA DEMONSTRATING COMPELLING ANTITUMOR ACTIVITY IN HPV-ASSOCIATED OROPHARYNGEAL SQUAMOUS CELL CARCINOMA (HPV+ OPSCC) AT THE 1.8 MG/KG Q2W DOSING REGIMEN

SAN DIEGO, MAY 06, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDED HIGHLIGHTS ON ITS CLINICAL PROGRAMS.

BIOATLA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

SAN DIEGO, APRIL 30, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT THE COMPANY'S MANAGEMENT WILL PROVIDE A CORPORATE UPDATE AND PARTICIPATE IN ONE-ON-ONE INVESTOR MEETINGS AT THE CITIZENS LIFE SCIENCES CONFERENCE, TO BE HELD IN NEW YORK, NY MAY 7-8, 2025.

BIOATLA TO PARTICIPATE IN THE CITIZENS LIFE SCIENCES CONFERENCE

SAN DIEGO, APRIL 29, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED THAT IT PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON TUESDAY, MAY 6, 2025 AT 4:30 P.M. ET TO DISCUSS ITS FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025 AND PROVIDE BUSINESS HIGHLIGHTS.

BIOATLA TO ANNOUNCE FIRST QUARTER 2025 FINANCIAL RESULTSAND PROVIDE BUSINESS HIGHLIGHTS ON MAY 6, 2025

SAN DIEGO, APRIL 23, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED A POSTER PRESENTATION AT THE UPCOMING 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING TO BE HELD ONLINE AND AT THE MCCORMICK PLACE CONVENTION CENTER IN CHICAGO, ILLINOIS FROM MAY 30JUNE 3, 2025.

BIOATLA ANNOUNCES UPCOMING POSTER PRESENTATION AT THE 2025 AMERICAN SOCIETY OF CLINICAL ONCOLOGY (ASCO) ANNUAL MEETING

SAN DIEGO, MARCH 27, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED ITS FINANCIAL RESULTS FOR THE FOURTH QUARTER AND FULL YEAR ENDED DECEMBER 31, 2024, AND PROVIDED HIGHLIGHTS ON ITS CLINICAL PROGRAMS.

BIOATLA REPORTS FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PROGRESS

SAN DIEGO, MARCH 20, 2025 (GLOBE NEWSWIRE) -- BIOATLA, INC. (NASDAQ: BCAB), A GLOBAL CLINICAL-STAGE BIOTECHNOLOGY COMPANY FOCUSED ON THE DEVELOPMENT OF CONDITIONALLY ACTIVE BIOLOGIC (CAB) ANTIBODY THERAPEUTICS FOR THE TREATMENT OF SOLID TUMORS, TODAY ANNOUNCED TWO ABSTRACTS ACCEPTED FOR POSTER PRESENTATIONS AT THE UPCOMING EUROPEAN LUNG CANCER CONGRESS (ELCC) 2025 SCIENTIFIC COMMITTEE AND MAYO CLINIC MULTIDISCIPLINARY HEAD AND NECK CANCER SYMPOSIUM 2025, TO BE HELD IN PARIS, FRANCE FROM MARCH 2629, 2025 AND IN SCOTTSDALE, AZ FROM MARCH 2729, 2025, RESPECTIVELY.

BioAtla, Inc.

BCAB

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BioAtla, Inc.

BCAB.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

BCAB